ArticleActas espanolas de psiquiatria2024
The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.
Article in Actas espanolas de psiquiatria, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD), a prevalent neurological condition, is characterized by the progressive degeneration of dopamine-producing neurons, leading to motor dysfunction and non-motor symptoms. Therefore, this study aimed to evaluate the impact of combining levodopa/benserazide with pramipexole on PD patients, focusing on cognitive function, plasma monoamine neurotransmitter levels, and serum growth differentiation factor-15 (GDF-15) and angiopoietin-1 (Ang-1) levels.
methodsThis retrospective study included 120 PD patients admitted to the hospital between January 2021 and January 2023. Based on the treatment approaches, the patients were categorized into the control group (n = 61) and the observation group (n = 59). The control group received oral levodopa/benserazide tablets, while the observation group was treated with levodopa/benserazide tablets combined with pramipexole. The two experimental groups were assessed and compared across several parameters, including PD symptoms [Unified Parkinson's Disease Rating Scale (UPDRS)], cognitive function [Montreal Cognitive Assessment (MoCA)], the levels of plasma monoamine neurotransmitters, and serum GDF-15 and Ang-1 levels.
resultsThe response rate to treatment was more significant in the observation group (96.55%) compared to the control group (87.93%, p = 0.162). Post-treatment, both groups demonstrated a decline in their UPDRS and overall scores, with the observation group indicating substantially lower scores than the control group (p < 0.05). Furthermore, both groups showed improvements in MoCA scores, with the observation group exhibiting higher scores than the control group (p < 0.05). Similarly, we observed significantly increased dopamine, 5-hydroxytryptamine, and norepinephrine levels in both groups, with the observation group showing a more pronounced increase (p < 0.05). Additionally, we observed a significant decrease in serum GDF-15 levels and an increase in Ang-1 levels across both groups after treatment. However, the observation group exhibited lower GDF-15 levels and higher Ang-1 levels than the control group (p < 0.05).
conclusionsThe combined use of levodopa/benserazide and pramipexole proves beneficial for managing PD. This therapeutic regimen can improve cognitive abilities and plasma monoamine neurotransmitter levels in PD patients, reduce brain tissue damage and decrease serum levels of GDF-15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.